AN2 Therapeutics, Inc.
General ticker "ANTX" information:
- Sector: Health Care
- Industry: Pharmaceuticals
- Capitalization: $36.6M (TTM average)
AN2 Therapeutics, Inc. does not follow the US Stock Market performance with the rate: -3.0%.
Estimated limits based on current volatility of 2.8%: low 1.04$, high 1.10$
Factors to consider:
- Total employees count: 36 as of 2022
- Top business risk factors: Labor/talent shortage/retention, Limited operating history, Operational and conduct risks, Transition risks, Funding requirements
- Earnings for 9 months up through Q3 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [1.10$, 4.12$]
- 2025-12-31 to 2026-12-31 estimated range: [1.14$, 4.19$]
Financial Metrics affecting the ANTX estimates:
- Positive: with PPE of -0.8 at the end of fiscal year the price was low
- Negative: negative Operating income
- Positive: Interest expense per share per price, % of 0 <= 0.01
- Positive: Shareholder equity ratio, % of 88.88 > 63.39
- Positive: Investing cash flow per share per price, % of 134.90 > -0.66
- Positive: Industry inventory ratio change (median), % of 0 <= 0
- Negative: negative Industry operating cash flow (median)
Short-term ANTX quotes
Long-term ANTX plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $42.26MM | $69.64MM | $54.55MM |
| Operating Income | $-42.26MM | $-69.64MM | $-54.55MM |
| Non-Operating Income | $1.31MM | $4.90MM | $3.23MM |
| R&D Expense | $29.51MM | $54.87MM | $40.49MM |
| Income(Loss) | $-40.96MM | $-64.73MM | $-51.32MM |
| Profit(Loss)* | $-40.96MM | $-64.73MM | $-51.32MM |
| Stockholders Equity | $95.37MM | $124.70MM | $81.85MM |
| Assets | $102.56MM | $138.74MM | $92.09MM |
| Operating Cash Flow | $-33.46MM | $-53.29MM | $-49.26MM |
| Investing Cash Flow | $-21.77MM | $-43.28MM | $54.59MM |
| Financing Cash Flow | $70.36MM | $84.99MM | $0.37MM |
| Earnings Per Share** | $-2.67 | $-2.74 | $-1.72 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.